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Significance of activation of neurohumoral regulation systems in clinics and treatment of chronic heart failure are 
formulated in that pоsitions based on world literature data. Basic positions about role of angiotensin-converting enzyme 
inhibitors in treatment of chronic heart failure patients with arterial hypertension are reflected in scientific works.  
 Each of components of the metabolic syndrome is well-known risk factor of chronic heart failure, and high 
atherogenicity of their clustering seems to be due to their metabolic interrelationships.  
The screening of chronic heart failure in 68 patients with metabolic syndrome has been done. Echocardiographic 
criteria of left ventricle myocardial dysfunction were studied and their significance in chronic heart failure patients with 
arterial hypertension and metabolic syndrome. One can see the positive effect of lisinopril (one of angiotensin-
converting enzyme inhibitors) on functional state of left ventricle. 
The paper presents the effects of long-term (during 6 month) treatment with lovastatin on plasma lipids 
composition clinical course of ischaemic heart disease in patients with arterial hypertension and metabolic syndrome. 
Patients with stable angina pectoris, functional class ІІ-ІІІ, and metabolic syndrome, were investigated. The results 
obtained show that lovastatin improved the coronary flow in people with ischaemic heart disease and metabolic 
syndrome. The anti-ischaemic effect of drug was determined hypolipidemic effect and protective influence of lovastatin 
on state of endothelium. Lovastatin has not harmful supplementary effects.           
So one can see the positive effect of lisinopril on functional state of left ventricle; and the anti-ischaemic effect, 
the hypolipidemic effect and the protective influence on state of endothelium of lovastatin in chronic heart failure 
patients with arterial hypertension and metabolic syndrome. 
 
